2einhalb | Noscendo GmbH

Heiner Dreismann joins Noscendo’s Board of Directors

by 2einhalb | Oct 5, 2021 | news

Duisburg, October 5, 2021 – Noscendo GmbH, a leading diagnostic company for identification and assessment of bloodstream associated pathogens and other infections announced today the addition of Heiner Dreismann, former President and CEO of Roche Molecular Systems, to...

A Case Report of Invasive Cerebral Aspergillosis

by 2einhalb | May 21, 2021 | news

Next-Generation Sequencing-Based Decision Support for Intensivists in Difficult-to-Diagnose Disease States. Aspergillus spp. are widespread environmental pathogens that can induce invasive aspergillosis, especially in immunocompromised patients. An 86-year-old female...

Mission: Saving patient lives

by 2einhalb | May 20, 2021 | press

Labor Dr. Limbach Heidelberg signs cooperation agreement with Noscendo Noscendo is committed to supporting physicians, clinics and laboratories in their daily work in the field of pathogen detection and to provide therapy-relevant results that directly benefit...

SensID and Noscendo combine forces to develop a contamination-free reference material

by 2einhalb | Oct 14, 2020 | press

Rostock, October 14th, 2020 – SensID and Noscendo combine forces to develop a contamination-free reference material with known human DNA quantity and virus status for clinical system validation. The reference material is developed by SensID and tested by...

Faster pathogen identification with new method

by 2einhalb | May 14, 2020 | press

Mainz, 14.05.2020. In hospitals in Germany, infections are one of the greatest challenges. So-called sepsis, colloquially also known as blood poisoning, accounts for a major portion of these infections. According to a study by Jena University Hospital, nationwide...